{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104977",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104977",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for citalopram and CYP2C19",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA449015",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA449015",
    "name" : "citalopram"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA124",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA124",
    "symbol" : "CYP2C19",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 19"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>For CYP2C19 ultrarapid metabolizers, monitor citalopram plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event, or select an alternative drug.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram based on <em>CYP2C19</em> genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They conclude to monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine) for the <em>CYP2C19</em> UM phenotype.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> <em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3) </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio (INR) increase &lt; 4.5 <br/>Kinetic effect (statistically significant difference) </td></tr><tr><td> <em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3) </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5 <br/>Kinetic effect (statistically significant difference) </td></tr><tr><td> <em>CYP2C19</em> UM (*17/*17) </td><td> Monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine) </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints </td><td> Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5 <br/>Kinetic effect (statistically significant difference) </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>Please see attached PDF for detailed information about the evaluated studies: <a href=\"/download.do?objCls=Attachment&amp;objId=_es_citalopram_CYP2C19_271111.pdf\" title=\"link tip\">Citalopram CYP2C19</a></li></ul>"
}